Sara Biagiotti / Ricercatrice Legge 240/10 a tempo determinato

1: Biagiotti S, Barone A, Aliano MP, Federici G, Malatesta M, Caputi C, Soddu S, Leuzzi V, Chessa L, Magnani M. Functional Classification of the ATM Variant c.7157C>A and <i>In Vitro</i> Effects of Dexamethasone. Front Genet. 2021 Oct 25;12:759467. doi: 10.3389/fgene.2021.759467. PMID: 34759960; PMCID: PMC8573154.

2: Bagaloni I, Visani A, Biagiotti S, Ruzzo A, Navari M, Etebari M, Mundo L, Granai M, Lazzi S, Isidori A, Loscocco F, Li J, Leoncini L, Visani G, Magnani M, Piccaluga PP. Metabolic Switch and Cytotoxic Effect of Metformin on Burkitt Lymphoma. Front Oncol. 2021 Sep 2;11:661102. doi: 10.3389/fonc.2021.661102. PMID: 34557403; PMCID: PMC8454268.

3: Biagiotti S, Bianchi M, Rossi L, Chessa L, Magnani M. Activation of NRF2 by dexamethasone in ataxia telangiectasia cells involves KEAP1 inhibition but not the inhibition of p38. PLoS One. 2019 May 20;14(5):e0216668. doi:10.1371/journal.pone.0216668. PMID: 31107893; PMCID: PMC6527213.

4: Menotta M, Biagiotti S, Orazi S, Rossi L, Chessa L, Leuzzi V, D'Agnano D, Plebani A, Soresina A, Magnani M. In vivo effects of dexamethasone on blood gene expression in ataxia telangiectasia. Mol Cell Biochem. 2018
Jan;438(1-2):153-166. doi: 10.1007/s11010-017-3122-x. Epub 2017 Jul 25. PMID:28744812.

5: Menotta M, Biagiotti S, Spapperi C, Orazi S, Rossi L, Chessa L, Leuzzi V, D'Agnano D, Soresina A, Micheli R, Magnani M. ATM splicing variants as
biomarkers for low dose dexamethasone treatment of A-T. Orphanet J Rare Dis. 2017 Jul 5;12(1):126. doi: 10.1186/s13023-017-0669-2. PMID: 28679388; PMCID:PMC5498894.

6: Menotta M, Biagiotti S, Bartolini G, Marzia B, Orazi S, Germani A, Chessa L, Magnani M. Nano-Mechanical Characterization of Ataxia Telangiectasia Cells
Treated with Dexamethasone. Cell Biochem Biophys. 2017 Mar;75(1):95-102. doi:10.1007/s12013-016-0775-0. Epub 2016 Dec 8. PMID: 27933465.

7: Biagiotti S, Menotta M, Orazi S, Spapperi C, Brundu S, Fraternale A, Bianchi M, Rossi L, Chessa L, Magnani M. Dexamethasone improves redox state in ataxia
telangiectasia cells by promoting an NRF2-mediated antioxidant response. FEBS J. 2016 Nov;283(21):3962-3978. doi: 10.1111/febs.13901. Epub 2016 Oct 12. PMID:27636396.

8: Menotta M, Biagiotti S, Streppa L, Rossi L, Magnani M. Label-free quantification of Tacrolimus in biological samples by atomic force microscopy. Anal Chim Acta. 2015 Jul 16;884:90-6. doi: 10.1016/j.aca.2015.05.014. Epub 2015 May 12. PMID: 26073814.

9: Menotta M, Biagiotti S, Bianchi M, Chessa L, Magnani M. Dexamethasone partially rescues ataxia telangiectasia-mutated (ATM) deficiency in ataxia telangiectasia by promoting a shortened protein variant retaining kinase
activity. J Biol Chem. 2012 Nov 30;287(49):41352-63. doi:10.1074/jbc.M112.344473. Epub 2012 Oct 10. PMID: 23055520; PMCID: PMC3510833.

10: Biagiotti S, Menotta M, Giacomini E, Radici L, Bianchi M, Bozzao C, Chessa L, Magnani M. Forward subtractive libraries containing genes transactivated by dexamethasone in ataxia-telangiectasia lymphoblastoid cells. Mol Cell Biochem. 2014 Jul;392(1-2):13-30. doi: 10.1007/s11010-014-2013-7. Epub 2014 Mar 14. PMID:24627244.

11: Biagiotti S, Paoletti MF, Fraternale A, Rossi L, Magnani M. Drug delivery by red blood cells. IUBMB Life. 2011 Aug;63(8):621-31. doi: 10.1002/iub.478. Epub 2011 Jul 15. PMID: 21766411.

12: Biagiotti S, Rossi L, Bianchi M, Giacomini E, Pierigè F, Serafini G, Conaldi PG, Magnani M. Immunophilin-loaded erythrocytes as a new delivery strategy for immunosuppressive drugs. J Control Release. 2011 Sep 25;154(3):306-13. doi:10.1016/j.jconrel.2011.05.024. Epub 2011 May 27. PMID: 21640771.

13: Pierigè F, De Marco C, Orlotti N, Dominici S, Biagiotti S, Serafini S, Zaffaroni N, Magnani M, Rossi L. Cytotoxic activity of 2-Fluoro-ara-AMP and2-Fluoro-ara-AMP-loaded erythrocytes against human breast carcinoma cell lines. Int J Oncol. 2010 Jul;37(1):133-42. doi: 10.3892/ijo_00000661. PMID: 20514405.